The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.

In conclusion, the EGFR/CD13 bi-targeted fusion protein ER(Fv)‑LDP-NGR displays multi-functional characteristics, acting on both cancer cells and endothelial cells. It might be an effective agent for targeted cancer therapy. PMID: 29130101 [PubMed - in process]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research